NUVL

$GSK $NUVL 🚨🚨🚨🚨 GlaxoSmithKline announced its intention to purchase U.S. biopharmaceutical firm Nuvalent in a deal valued at approximately $10.6 billion. GSK plans to initiate a tender offer for all outstanding Nuvalent shares at $124 each, reflecting a 40% premium over Nuvalent's recent closing price. The acquisition is expected to enhance GSK's oncology pipeline with three lung cancer assets, including therapies currently under FDA review, which could receive U.S. approvals by 2026.

$GSK media day presentation re $NUVL acquisition. cc $SPRO Ashleigh Furlong (Bloomberg): You mentioned building the oncology portfolio brick-by-brick. I wonder if that house is built yet, and you are happy with where you are? Luke Miels: ****** We remain active, not just in oncology but also other areas where we have expertise.****** What we are looking to employ is a strategy that combines a commitment to innovation but also strong discipline in terms of creating value for our shareholders. We remain active at looking but, again, we first need to digest this transaction, so I think it is one step at a time at this point. Thanks, Ashleigh. https://www.sec.gov/Archives/edgar/data/1131399/000119312526264048/d142612dex99a5b.htm

$IDYA analyst consensus revenue estimates versus $NUVL & $ACLX via graph & simple 5-year revenue multiple comparison. ACLX was acquired for an EV of $7.3B & NUVB was $9.4B (rounded). None of the 3 have a FDA approved therapy yet though obviously NUVL & ACLX had active PDUFA dates when acquired. Our simple question...if analysts believe IDYA will meaningfully outsell ACLX and, more or less, generate revenues consistent with NUVL, does this suggest IDYA's risk v reward profile is compelling? Are there any reasons IDYA's valuation as a multiple of analysts estimates won't match the 2 (assuming BLA's are submitted)? This is not investment advice. $XBI $NBI

This is not investment advice. We have no idea what $RVMD might be worth in a hypothetical acquisition. That being said, $NUVL & $ACLX were acquired for an average of 1.5X analyst 5-year FY28 - 32 revenue estimates, excluding the highest estimate for each year, as detailed on the attachment. The 7 RVMD analysts that provide RVMD FY28 - 32 revenue estimates project RVMD to generate $28.421B in revenues over the same 5-year period. Hence if RVMD analyst estimates were credible AND if RVMD were acquired at the same average 5-year revenue multiple of 1.5X (2 ENORMOUS IFs) then RVMD would exit for $42.63B in EV (consistent with NUVL & ACLX multiples). Using RVMD's 3/31/26 cap table, this would be ~$200 per share. We're curious if investors believe RVMD's profile would merit a peer M&A revenue multiple consistent with NUVL & ACLX? Why or why not (i.e. gross margin profile is different, royalty obligations)? We'd genuinely appreciate feedback. This is not investment advice. $XBI $IBB

$GSK CEO Luke Miels was the architect behind the 2022 $SPRO equity investment and license agreement for tebipenem (effectively saving SPRO and tebi). He seemed to like it then! How about now as the CEO, with FDA approval any time? Now he LOVES oncology and pivoting GSK portfolio back into cancer drugs with $10.6 billion acquisition of Cambridge MA biotech Nuvalent $NUVL. Perhaps they will go fishing in those "dirty waters" of the Charles River again ..... I'm not an expert but AI tells me Immunitas single cell genomics platform and IMT-009 works well in combination with GSK current oncology franchise, particularly jemperli. So Mr Miels can (1) achieve the completion of his Tebi vision and (2) roll his SPRO shares into Immunitas to gain a toehold ... get a front row look at the science, off-load some R&D onto Immunitas balance sheet AND maybe acquire the rest at a later date. No capital gains on its SPRO investment AND get shot on goal with new oncology science project.

$NUVB Stan Druckenmiller purchased over 4.5 million Shares!! $NUVB going to be the next $NUVL

$NUVL https://anachart.com/wp-content/uploads/2026/06/1781121702_soc-img.jpg

$GSK bigger ambitions in oncology: WSJ reverse merge target: something that aligns with $NUVL and jemperli? cc $SPRO + Immunitas https://www.wsj.com/health/pharma/new-gsk-ceos-cancer-deal-signals-bigger-ambitions-c49bf888

$NUVL https://www.barchart.com/story/news/2388163/nuvalent-stock-hits-all-time-high-following-gsk-s-buyout-offer

$NUVL Neutral Recommendation Issued On NUVL By UBS https://marketwirenews.com/stock/nuvl/news/neutral-recommendation-issued-on-nuvl-by-ubs-6827836707245181.html?utm_source=stocktwits